Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation

Sponsor

AlRefaey Kandeel (Other)

Overall Status

Unknown status

CT.gov ID

NCT02544906

Collaborator

(none)

120

Enrollment

Location

Arms

Duration (Months)

9.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The use of propofol or dexmedetomedine for prevention of sevofurane emergence agitation in LDLT recipients

Condition or Disease	Intervention/Treatment	Phase
Liver Transplantation	Drug: Propofol Drug: dexmedetomedine	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

120 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Participant)

Primary Purpose:

Prevention

Study Start Date :

Sep 1, 2015

Anticipated Primary Completion Date :

Oct 1, 2016

Anticipated Study Completion Date :

Oct 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
No Intervention: Control No drugs will be given. the emergence agitation will be monitored and recorded
Experimental: Propofol group Propofol at dose of 1 mg/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded	Drug: Propofol Infusion of propofol to prevent emergence agitation in liver transplanta recipients
Experimental: dexmedetomedine group dexmedetomedine at dose of .5 mic/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded	Drug: dexmedetomedine Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients

Arm

Intervention/Treatment

No Intervention: Control

No drugs will be given. the emergence agitation will be monitored and recorded

Experimental: Propofol group

Propofol at dose of 1 mg/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded

Drug: Propofol

Infusion of propofol to prevent emergence agitation in liver transplanta recipients

Experimental: dexmedetomedine group

dexmedetomedine at dose of .5 mic/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded

Drug: dexmedetomedine

Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients

Outcome Measures

Primary Outcome Measures

incidence of emergence agitation in liver trasnplant recipients [24 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:

30 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

All recipients of living donor liver transplantation

Exclusion Criteria:

patient refusal Allergy to either propofol or dexmedetomediene CNS disease

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Mansoura university	Mansoura	Dkahleya	Egypt

Sponsors and Collaborators

AlRefaey Kandeel

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

AlRefaey Kandeel, Dr, Mansoura University

ClinicalTrials.gov Identifier:

NCT02544906

Other Study ID Numbers:

LTx 7

First Posted:

Sep 9, 2015

Last Update Posted:

Sep 9, 2015

Last Verified:

Sep 1, 2015

Keywords provided by AlRefaey Kandeel, Dr, Mansoura University

recipients

Additional relevant MeSH terms:

Propofol

Study Results

No Results Posted as of Sep 9, 2015